normative
Cancer Therapy Risk-Benefit Justifies Experiments
Commercial applications of synthetic cells focus on the deadliest cancers because the risk-to-benefit ratio makes experimental therapies acceptable when the disease is almost certain to kill the patient, whereas conditions like allergies would not justify such experimental risk; cancer is also not one disease but many variable ones, making generic kill-everything drugs inefficient.
normativepending
Speaker
Kate AdamalaEvidence Quote
“a patient who has six months left to live, if you extend that life span by another six months, you... You've done something good.”
Created: 6/13/2026, 12:25:47 AM
Your notes
Loading notes...